neostigmine has been researched along with Abdominal Pain in 11 studies
Neostigmine: A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike PHYSOSTIGMINE, does not cross the blood-brain barrier.
neostigmine : A quaternary ammonium ion comprising an anilinium ion core having three methyl substituents on the aniline nitrogen, and a 3-[(dimethylcarbamoyl)oxy] substituent at position 3. It is a parasympathomimetic which acts as a reversible acetylcholinesterase inhibitor.
Abdominal Pain: Sensation of discomfort, distress, or agony in the abdominal region.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In patients with acute colonic pseudo-obstruction who have not had a response to conservative therapy, treatment with neostigmine rapidly decompresses the colon." | 9.09 | Neostigmine for the treatment of acute colonic pseudo-obstruction. ( Kimmey, MB; Ponec, RJ; Saunders, MD, 1999) |
| " Here we report the development of a new, minimally invasive behavioral model of abdominal pain induced by ip administration of neostigmine in mice." | 7.78 | New neostigmine-based behavioral mouse model of abdominal pain. ( Altier, C; Chapman, K; Fichna, J; Janecka, A; Lapointe, T; Storr, MA; Vergnolle, N, 2012) |
| "Sickle cell disease is a disorder that produces significant morbidity and mortality." | 5.35 | Acute colonic pseudoobstruction in a child with sickle cell disease treated with neostigmine. ( Khosla, A; Ponsky, TA, 2008) |
| "Neostigmine is a treatment option for colonic pseudoobstruction." | 5.34 | Use of neostigmine to relieve a suspected colonic pseudoobstruction in pregnancy. ( Rausch, ME; Rosen, T; Troiano, NH, 2007) |
| "In patients with acute colonic pseudo-obstruction who have not had a response to conservative therapy, treatment with neostigmine rapidly decompresses the colon." | 5.09 | Neostigmine for the treatment of acute colonic pseudo-obstruction. ( Kimmey, MB; Ponec, RJ; Saunders, MD, 1999) |
| "To determine the effect of intramuscular administration of Neostigmine® on the visualization of the pancreatic duct on magnetic resonance cholangiopancreatography in patients with recurrent acute pancreatitis or abdominal pain." | 4.12 | Neostigmine® Improves Pancreatic Duct Visualization in Magnetic Resonance Cholangiopancreatography and Could Be a Cheap Alternative for Secretin. ( Araya, F; Berger, Z; Cárdenas, G; Simian, D; Toledo, PF, 2022) |
| " Here we report the development of a new, minimally invasive behavioral model of abdominal pain induced by ip administration of neostigmine in mice." | 3.78 | New neostigmine-based behavioral mouse model of abdominal pain. ( Altier, C; Chapman, K; Fichna, J; Janecka, A; Lapointe, T; Storr, MA; Vergnolle, N, 2012) |
| "Sickle cell disease is a disorder that produces significant morbidity and mortality." | 1.35 | Acute colonic pseudoobstruction in a child with sickle cell disease treated with neostigmine. ( Khosla, A; Ponsky, TA, 2008) |
| "Neostigmine is a treatment option for colonic pseudoobstruction." | 1.34 | Use of neostigmine to relieve a suspected colonic pseudoobstruction in pregnancy. ( Rausch, ME; Rosen, T; Troiano, NH, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (18.18) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Toledo, PF | 1 |
| Cárdenas, G | 1 |
| Berger, Z | 1 |
| Simian, D | 1 |
| Araya, F | 1 |
| Reeves, M | 1 |
| Frizelle, F | 1 |
| Wakeman, C | 1 |
| Parker, C | 1 |
| Khan, MW | 1 |
| Ghauri, SK | 1 |
| Shamim, S | 1 |
| Khosla, A | 1 |
| Ponsky, TA | 1 |
| Bonnett, TJ | 1 |
| Lashen, H | 1 |
| Xie, H | 1 |
| Peereboom, DM | 1 |
| Fichna, J | 1 |
| Lapointe, T | 1 |
| Chapman, K | 1 |
| Janecka, A | 1 |
| Vergnolle, N | 1 |
| Altier, C | 1 |
| Storr, MA | 1 |
| Rausch, ME | 1 |
| Troiano, NH | 1 |
| Rosen, T | 1 |
| Bawaskar, HS | 1 |
| Bawaskar, PH | 1 |
| Fukudo, S | 1 |
| Nomura, T | 1 |
| Muranaka, M | 1 |
| Taguchi, F | 1 |
| Ponec, RJ | 1 |
| Saunders, MD | 1 |
| Kimmey, MB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A New Approach of Neostigmine in Unavoidable Post Operative Ileus After Surgery[NCT00676377] | Phase 4 | 3 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| The Curative Effect and Security of Neostigmine Treatment of Acute Pancreatitis Combined With Intra-abdominal Hypertension[NCT02543658] | Phase 2 | 80 participants (Actual) | Interventional | 2015-09-01 | Completed | ||
| Evaluating the Safety and Efficacy of Different Routes of Neostigmine Administration for Acute Colonic Pseudo Obstruction: a Prospective Randomized Trial[NCT04951726] | Phase 4 | 90 participants (Anticipated) | Interventional | 2022-02-04 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Days in hospital within 6 months after randomisation (NCT02543658)
Timeframe: From randomisation to 6 months
| Intervention | days (Median) |
|---|---|
| Neostigmine | 20 |
| Conservative Treatment | 19 |
Days in ICU within 6 months after randomisation (NCT02543658)
Timeframe: From randomisation to 6 months
| Intervention | days (Median) |
|---|---|
| Neostigmine | 12 |
| Conservative Treatment | 12 |
Death during from randomization to 90 days after onset. (NCT02543658)
Timeframe: From randomization to 90 days after onset.
| Intervention | Participants (Count of Participants) |
|---|---|
| Neostigmine | 10 |
| Conservative Treatment | 11 |
Medical expenses within 6 months after randomisation (NCT02543658)
Timeframe: From randomisation to 6 months
| Intervention | thousand(RMB) (Median) |
|---|---|
| Neostigmine | 95.3 |
| Conservative Treatment | 102.3 |
Abdominal compartment syndrome is defined as a sustained IAP>20 mmHg (with or without an APP<60 mmHg) that is associated with new organ dysfunction/failure (NCT02543658)
Timeframe: From randomization to discharge or death, assessed up to 4 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Neostigmine | 2 |
| Conservative Treatment | 4 |
Incidence of organ failure from randomization to discharge or death, assessed up to 3 months (NCT02543658)
Timeframe: From randomization to discharge or death, assessed up to 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Neostigmine | 12 |
| Conservative Treatment | 16 |
Due to that neostigmine has an inhibitory effect on the cardiovascular system, new-onset cardiovascular failure after grouping is considered as a possible adverse event related to neostigmine.Cardiovascular failure was defined as circulatory systolic blood pressure <90 mm Hg, despite adequate fluid resuscitation, or need for inotropic catecholamine support (NCT02543658)
Timeframe: From randomization to 7 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Neostigmine | 8 |
| Conservative Treatment | 4 |
IAP rebound ≥ 5mmHg or increase ≥ 20mmHg within 1-7 days after grouping (NCT02543658)
Timeframe: From randomization to 7 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Neostigmine | 4 |
| Conservative Treatment | 8 |
From date of randomization to enteral nutrition, assessed up to 30 days (NCT02543658)
Timeframe: Start time of enteral nutrition after randomization, assessed up to 30 days
| Intervention | days (Median) |
|---|---|
| Neostigmine | 3 |
| Conservative Treatment | 4 |
Monitor the intra-abdominal pressure within 1 to 7 days after randomization, and calculate the percent change compared with that before randomization (NCT02543658)
Timeframe: From randomization to 7 days after treatment,Measured IAP every 6 hours
| Intervention | percent change of IAP (Median) | |
|---|---|---|
| percent change of IAP at 24 hours | percent change of IAP at 7 days | |
| Conservative Treatment | -5.4 | -20.0 |
| Neostigmine | -18.7 | -27.2 |
After randomization, the change of stool volume (ML) was calculated every 24 hours.For example, the amount of stool volume decreased or increased in 24 hours after grouping compared to before grouping. (NCT02543658)
Timeframe: From randomization to 7 days
| Intervention | ml/day (Median) | |
|---|---|---|
| The change of stool volume at 24 hours | The change of stool volume at 7th day | |
| Conservative Treatment | 60 | 370 |
| Neostigmine | 870 | 1025 |
1 trial available for neostigmine and Abdominal Pain
| Article | Year |
|---|---|
Neostigmine for the treatment of acute colonic pseudo-obstruction.
Topics: Abdominal Pain; Acute Disease; Adult; Aged; Aged, 80 and over; Cholinesterase Inhibitors; Colonic Ps | 1999 |
Neostigmine for the treatment of acute colonic pseudo-obstruction.
Topics: Abdominal Pain; Acute Disease; Adult; Aged; Aged, 80 and over; Cholinesterase Inhibitors; Colonic Ps | 1999 |
Neostigmine for the treatment of acute colonic pseudo-obstruction.
Topics: Abdominal Pain; Acute Disease; Adult; Aged; Aged, 80 and over; Cholinesterase Inhibitors; Colonic Ps | 1999 |
Neostigmine for the treatment of acute colonic pseudo-obstruction.
Topics: Abdominal Pain; Acute Disease; Adult; Aged; Aged, 80 and over; Cholinesterase Inhibitors; Colonic Ps | 1999 |
Neostigmine for the treatment of acute colonic pseudo-obstruction.
Topics: Abdominal Pain; Acute Disease; Adult; Aged; Aged, 80 and over; Cholinesterase Inhibitors; Colonic Ps | 1999 |
Neostigmine for the treatment of acute colonic pseudo-obstruction.
Topics: Abdominal Pain; Acute Disease; Adult; Aged; Aged, 80 and over; Cholinesterase Inhibitors; Colonic Ps | 1999 |
Neostigmine for the treatment of acute colonic pseudo-obstruction.
Topics: Abdominal Pain; Acute Disease; Adult; Aged; Aged, 80 and over; Cholinesterase Inhibitors; Colonic Ps | 1999 |
Neostigmine for the treatment of acute colonic pseudo-obstruction.
Topics: Abdominal Pain; Acute Disease; Adult; Aged; Aged, 80 and over; Cholinesterase Inhibitors; Colonic Ps | 1999 |
Neostigmine for the treatment of acute colonic pseudo-obstruction.
Topics: Abdominal Pain; Acute Disease; Adult; Aged; Aged, 80 and over; Cholinesterase Inhibitors; Colonic Ps | 1999 |
10 other studies available for neostigmine and Abdominal Pain
| Article | Year |
|---|---|
Neostigmine® Improves Pancreatic Duct Visualization in Magnetic Resonance Cholangiopancreatography and Could Be a Cheap Alternative for Secretin.
Topics: Abdominal Pain; Acute Disease; Adolescent; Adult; Cholangiopancreatography, Endoscopic Retrograde; C | 2022 |
Acute colonic pseudo-obstruction in pregnancy.
Topics: Abdominal Pain; Acute Disease; Adult; Anti-Bacterial Agents; Cesarean Section; Colonic Pseudo-Obstru | 2015 |
Ogilvie's Syndrome.
Topics: Abdominal Pain; Cholinesterase Inhibitors; Colonic Pseudo-Obstruction; Female; Humans; Middle Aged; | 2016 |
Acute colonic pseudoobstruction in a child with sickle cell disease treated with neostigmine.
Topics: Abdominal Pain; Acute Disease; Anemia, Sickle Cell; Blood Transfusion; Child, Preschool; Cholinester | 2008 |
A case of acute post-laparoscopy bowel hypermotility and treatment with hyoscine butylbromide.
Topics: Abdominal Pain; Butylscopolammonium Bromide; Female; Gastrointestinal Motility; Humans; Laparoscopy; | 2009 |
Ogilvie's syndrome during chemotherapy with high-dose methotrexate for primary CNS lymphoma.
Topics: Abdominal Pain; Aged; Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Colon; Colo | 2012 |
New neostigmine-based behavioral mouse model of abdominal pain.
Topics: Abdominal Pain; Animals; Disease Models, Animal; Male; Mice; Morphine; Neostigmine; Proto-Oncogene P | 2012 |
Use of neostigmine to relieve a suspected colonic pseudoobstruction in pregnancy.
Topics: Abdominal Pain; Adult; Colectomy; Colonic Pseudo-Obstruction; Diagnosis, Differential; Female; Human | 2007 |
Snakebite, cocktails, and a girl with a stomach ache.
Topics: Abdominal Pain; Animals; Antivenins; Bungarus; Child; Cholinesterase Inhibitors; Diagnosis, Differen | 2008 |
Brain-gut response to stress and cholinergic stimulation in irritable bowel syndrome. A preliminary study.
Topics: Abdominal Pain; Adult; Analysis of Variance; Brain; Cardiovascular System; Colonic Diseases, Functio | 1993 |